J. Apter, MD, MSc (PI), Timothy Rebbeck, PhD, Athanasios I. Zavras, DMD, MS, DrMS, Richard
Aplenc, MD, MSCE, Richard Spielman, PhD, Alexander Steven Whitehead,
Angela Haczku, MD, PhD
Do Genetic Susceptibilities
Play a Role
in Penicillin Allergy?
The goal of this HPE research is to
use penicillin allergy as a model for studying
genetic factors influencing medication responses with properties that
difficult to study, e.g. when the response is intermittent,
potentially life-threatening, has no gold standard phenotypic
for which no generally accepted animal model exists. As penicillin
all of these properties, it is a fitting model for exploring design and
methodologies to address one or more of these problems.
Specific Aims are to:
Our two hypotheses related
to penicillin allergy are
that: 1) polymorphisms of genes whose
products participate in the immediate hypersensitivity response, e.g., genes from Chromosome 5q23-35 whose products
include IL-4, IL-13, IL-9, IL –5, and IL-3, are associated with
increased risk of hypersensitivity and 2) products of polymorphisms of
metabolism genes, e.g. CYP3A4,
metabolize penicillin differently, enhancing
methods for studying medication responses that
are intermittent, unanticipated, potentially life-threatening, or have
phenotypic gold standard, using penicillin allergy as a model.
and test methods of identifying and obtaining
genetic material from patients with these medication responses, from
clinical databases in collaboration with investigators from Ingenix,
claims database of United Health Care.
transdisciplinary collaboration and apprenticeship of
allergy, epidemiology, genetics, pharmacology, and the health care
addressing Aims 1 and 2.
Through our interdisciplinary collaboration and with
Dr. Apter’s apprenticeship we will obtain appropriate pilot data for a
successful application for external funding.